An observational study in Relapsed or Refractory Chronic Lymphoproliferative Disorders, sponsored by Gruppo Italiano Studio Linfomi. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-10-21.
Sponsored by Gruppo Italiano Studio Linfomi · Observational
This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.
231 studies on the registry are indexed under Lymphoproliferative Disorders; 45 are open to participants now.
This study's enrollment of 109 is below the median of 241 across 37 observational studies indexed under Lymphoproliferative Disorders.
Browse Lymphoproliferative Disorders studies →Gruppo Italiano Studio Linfomi is the lead sponsor of 13 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients with relapsed or refractory chronic lymphoproliferative disorders treated with bendamustine +/- rituximab
Exclusion Criteria:
Drug: bendamustine +/- rituximab
overall response rate
Time frame: within 1 month after end of treatment
grade III and IV (NCI Common Toxicity Criteria) adverse events
Time frame: within 1 month after end of treatment
prognostic factors
Time frame: within 1 month after end of treatment
progression free survival
Time frame: within 1 month after end of treatment
overall survival
Time frame: within 1 month after end of treatment
This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoproliferative Disorders→
Gruppo Italiano Studio Linfomi